Pre-Made Atacicept Biosimilar, Fusion Protein targeting TNFSF13/APRIL fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD256/TALL-2/TALL2/TNLG7B/TRDL-1/UNQ383/PRO715/ZTNF2 for drug discovery and mechanism of action (MOA) research

Pre-Made Atacicept Biosimilar, Fusion Protein targeting TNFSF13/APRIL fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD256/TALL-2/TALL2/TNLG7B/TRDL-1/UNQ383/PRO715/ZTNF2 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Atacicept is a recombinant fusion protein designed to inhibit B cells, thereby suppressing autoimmune disease. The designer protein combines the binding site for two cytokines that regulate maturation, function, and survival of B cells - B-lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL), with the constant region of immunoglobin.[1] Atacicept blocks activation of B cells by the tumor necrosis factor receptor superfamily member 13B (more commonly known as TACI), a transmembrane receptor protein found predominantly on the surface of B cells. Like the monoclonal antibody belimumab, atacicept blocks the binding of BLyS, but it also blocks APRIL. Binding of these TACI ligands induces proliferation, activation, and longevity of B cells and thus their production of autoantibodies.[2] Atacicept is thought to selectively impair mature B cells and plasma cells with less impact on progenitor cells and memory B cells.[3]

Atacicept is a recombinant fusion protein designed to inhibit B cells, thereby suppressing autoimmune disease. Atacicept is a fully human recombinant fusion protein consisting of the Fc region of human IgG1 and the binding portion of transmembrane activator and CAML interactor (TACI; also known as tumor necrosis factor receptor superfamily member 13B), which is able to bind the cytokines B cell-activating factor (BAFF; also termed B-lymphocyte stimulator or BlyS) and a proliferation-inducing ligand (APRIL). Atacicept blocks activation of B cells by the tumor necrosis factor receptor superfamily member 13B (more commonly known as TACI), a transmembrane receptor protein found predominantly on the surface of B cells. Atacicept blocks the binding of BLyS, but it also blocks APRIL. Atacicept is thought to selectively impair mature B cells and plasma cells with less impact on progenitor cells and memory B cells.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-742-1mg	1mg	3090
GMP-Bios-INN-742-10mg	10mg	Inquiry
GMP-Bios-INN-742-100mg	100mg	Inquiry
GMP-Bios-INN-742-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Atacicept Biosimilar, Fusion Protein targeting TNFSF13/APRIL fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD256/TALL-2/TALL2/TNLG7B/TRDL-1/UNQ383/PRO715/ZTNF2
INN Name	Atacicept
Target	TNFSF13/APRIL
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [TNFRSF13B (tumor necrosis factor receptor (TNFR) superfamily member 13B, TACI, transmembrane activator and CAML Interactor)]2 - IGHG1 Fc (Fragment constant)
VD LC	Fusion - [TNFRSF13B (tumor necrosis factor receptor (TNFR) superfamily member 13B, TACI, transmembrane activator and CAML Interactor)]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Merck Serono International S.A. (Geneva Switzerland) / ZymoGenetics Inc. (Seattle WA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0